Thursday , October 19 2017
Home / Therapies / DPP-4 Therapy Center (page 10)

DPP-4 Therapy Center

ONGLYZA™ New DPP-4 Inhibitor (saxagliptin) Demonstrates Significant Reductions in Glucose

Results from a 24-week Phase III study showed that saxagliptin, a selective, reversible inhibitor of the dipeptidyl peptidase (DPP-4) enzyme in development by Bristol-Myers Squibb Company and AstraZeneca produced significant reductions in key measures of glucose control, A1C, FPG and PPG in treatment naïve people with type 2 diabetes compared ...

Read More »